Epizyme Company Profile (NASDAQ:EPZM)

Analyst Ratings

Consensus Ratings for Epizyme (NASDAQ:EPZM) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.50 (144.02% upside)

Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016JMP SecuritiesReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Leerink SwannReiterated RatingOutperform$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016MizuhoReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Royal Bank Of CanadaReiterated RatingOutperform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016WedbushReiterated RatingOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Citigroup Inc.Initiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015SunTrust Banks Inc.Initiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Epizyme (NASDAQ:EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.53)($0.41)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.65)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.59)($0.56)$5.42 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.70)($0.63)$2.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2015Q115($0.99)($1.75)$5.63 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.53)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.55)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.50)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.47)($0.22)$8.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epizyme (NASDAQ:EPZM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.63)($0.42)($0.51)
Q2 20164($0.68)($0.45)($0.55)
Q3 20164($0.73)($0.49)($0.61)
Q4 20164($0.77)($0.52)($0.63)
Q1 20171($0.63)($0.63)($0.63)
Q2 20171($0.65)($0.65)($0.65)
Q3 20171($0.67)($0.67)($0.67)
Q4 20171($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epizyme (NASDAQ:EPZM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Epizyme (NASDAQ:EPZM)
DateHeadline
07/21/16 04:01 PMEpizyme, Inc. (NASDAQ:EPZM) Updated Price Targets - FTSE News
07/21/16 04:01 PMEpizyme, Inc. (NASDAQ:EPZM) Updated Price Targets - FTSE News
07/21/16 07:22 AMEpizyme Incorporated (NASDAQ:EPZM) Shorted Shares Increased By 20.65% - Consumer Eagle
07/21/16 07:22 AMEarnings Focus and Crowd Sourced Sentiment Review for Epizyme, Inc. (NASDAQ:EPZM) - TGP
07/20/16 06:14 AMEpizyme, Inc. (NASDAQ:EPZM): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 09:57 AMTrading Performance and Target Watch for Epizyme, Inc. (NASDAQ:EPZM) - Press Telegraph
07/19/16 09:57 AMShare Performance Summary for: Epizyme, Inc. (NASDAQ:EPZM) - Press Telegraph
07/17/16 08:23 AMEcor1 Capital LLC Increased Epizyme INC (NASDAQ:EPZM) by $10.80 Million as Shares Declined - Consumer Eagle
07/16/16 07:14 AMShares Experiencing a Downtrend: Epizyme, Inc. (NASDAQ:EPZM) - TGP
07/15/16 06:29 AMEpizyme Inc. (EPZM) Drops 7.3% on July 13 - Equities.com
07/14/16 03:59 PMCrowd Rating and Earnings Recap for Epizyme, Inc. (NASDAQ:EPZM) - Telanagana Press
07/12/16 09:13 PMEpizyme, Inc. (NASDAQ:EPZM) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/10/16 08:21 AMEpizyme, Inc. (NASDAQ:EPZM) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 03:37 PMEcor1 Capital LLC Increased Epizyme INC (NASDAQ:EPZM) by $10.80 Million as Shares Declined - Press Telegraph
07/09/16 07:20 AMShares Finishing Down for the Week Epizyme, Inc. (NASDAQ:EPZM) - Engelwood Daily
07/09/16 07:20 AMSentiment Change Report: Epizyme Inc (NASDAQ:EPZM) - Engelwood Daily
07/06/16 03:57 PMEpizyme, Inc. (NASDAQ:EPZM) Current Analyst Ratings - Fiscal Standard
07/04/16 03:34 PMShare Performance Recap for: Epizyme, Inc. (NASDAQ:EPZM) - Press Telegraph
07/01/16 07:10 AMBrokers Issue Average Price Target Of 27.18 On Epizyme, Inc. (NASDAQ:EPZM) - Fiscal Standard
06/28/16 08:53 PMEpizyme Inc. (EPZM) Jumps 9.67% on June 28 - Equities.com
06/28/16 03:50 PMCheck on Share Volatility: Epizyme, Inc. (NASDAQ:EPZM) - Engelwood Daily
06/28/16 03:50 PMShare Update and Earnings Review for Epizyme, Inc. (NASDAQ:EPZM) - Press Telegraph
06/26/16 08:49 AMEpizyme Incorporated (NASDAQ:EPZM) Shorted Shares Increased By 2.18% - Press Telegraph
06/24/16 11:01 PM[$$] U.S. Cheese Prices Fall -
06/23/16 05:57 AMEpizyme Inc. (EPZM) is Trading Lower on Unusual Volume for June 20 - Equities.com
06/23/16 05:57 AMEpizyme (EPZM), Genentech (RHHBY) Enter Collaboration for Tazemetostat and Tecentriq Trial in NHL - StreetInsider.com
06/23/16 05:57 AMEpizyme Inc. (EPZM) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/22/16 03:57 PMEpizyme (EPZM), Genentech (RHHBY) Enter Collaboration for Tazemetostat and Tecentriq Trial in NHL
06/22/16 11:39 AMEpizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq™ (atezolizumab) for Treatment of Non-Hodgkin Lymphoma - [at noodls] - Clinical trial to evaluate Epizyme's clinical-stage EZH2 inhibitor in combination with anti-PD-L1 cancer immunotherapy CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage ...
06/21/16 03:38 PMWeekly Biotech Report Covering Epizyme Inc (EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd. (TEVA ... - Insider Monkey (blog)
06/21/16 07:35 AMEpizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : June 21, 2016 -
06/20/16 03:44 PMEpizyme (EPZM) Offers Prelim. Data from Tazemetostat Phase 2 in NHL; Favorable Safety Profile Noted
06/20/16 03:44 PMEpizyme to Continue Blood Cancer Trials as Tumors Were Wiped Out in Some Patients
06/20/16 03:44 PMWeekly Biotech Report Covering Epizyme Inc (NASDAQ:EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd. (NYSE:TEVA) drug Vantrela
06/20/16 02:22 PMWeekly Biotech Report Covering Epizyme Inc (EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd. (TEVA) Drug Vantrela -
06/20/16 10:04 AMEpizyme, Inc. (NASDAQ:EPZM) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 10:04 AMTrade-Ideas: Epizyme (EPZM) Is Today's Weak On High Relative Volume Stock - TheStreet.com
06/20/16 10:04 AMWeekly Biotech Report Covering Epizyme Inc (NASDAQ:EPZM) - Market Exclusive
06/20/16 08:05 AMEpizyme stock down 6% after worse than expected mid-phase trial results -
06/20/16 05:07 AMEPIZYME, INC. Files SEC form 8-K, Other Events -
06/20/16 01:48 AM2:48 am Epizyme reports early data from global Phase 2 trial of Tazemetostat demonstrating favorable safety profile consistent with prior clinical experience -
06/19/16 03:36 PMEpizyme Reports Data From Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma
06/19/16 06:59 AMEpizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting - [at noodls] - Tazemetostat demonstrates favorable safety profile consistent with prior clinical experience Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses ...
06/16/16 09:05 PMRecently Issued Stock Ratings For Epizyme, Inc. (NASDAQ:EPZM) - Fiscal Standard
06/16/16 02:30 PMRonald Muhlenkamp Sells JPMorgan, Morgan Stanley -
06/10/16 09:56 PMEpizyme Inc. (EPZM) Drops 5.62% on June 09 - Equities.com
06/10/16 03:57 PMEpizyme (EPZM): Today's Weak On High Volume Stock - TheStreet.com
06/09/16 07:56 AMEarnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy? -
06/08/16 09:57 PMEPIZYME INC. (NASDAQ:EPZM) Financial Condition Compared to S&P 500 - CML News
06/08/16 07:51 AMEpizyme Inc. (EPZM) Jumps 6.09% on June 06 - Equities.com

Social

About Epizyme

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPZM
  • CUSIP:
Key Metrics:
  • Previous Close: $10.14
  • 50 Day Moving Average: $10.76
  • 200 Day Moving Average: $10.55
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $574.51M
  • Beta: 2.2
  • Current Year EPS Consensus Estimate: $-2.11 EPS
  • Next Year EPS Consensus Estimate: $-2.62 EPS
Additional Links:
Epizyme (NASDAQ:EPZM) Chart for Saturday, July, 23, 2016